FOXP3 and cervical carcinoma: The double positive expression of VISTA and Foxp3 indicate the worst prognosis of cervical cancer patients, compared to the single negative group; the survival analysis shows that the single positive expression of VISTA has the worst average survival (35.114 ± 2.828 vs. 51.486 ± 1.403 months).